Educational information, not medical advice — ask your doctor or midwife.
Mokuboito is a four-herb Kampo formula composed of Boi (Sinomenium acutum or Stephania tetrandra), Gypsum (calcium sulfate mineral), Keishi (Cinnamomum cassia bark), and Ogi (Astragalus membranaceus root). It has been used in traditional East Asian medicine for over a thousand years to treat patterns described as 'water retention with heat' — conditions we now recognize as congestive heart failure and pulmonary edema. It remains a licensed Kampo prescription in Japan and is actively researched for cardiovascular applications.
The formula works through several complementary actions: sinomenine from the Boi root helps relax blood vessels and reduce fluid buildup by supporting kidney filtration and mildly lowering vascular resistance. Astragalus strengthens heart muscle function and supports immune balance, while cinnamon bark supports circulation. Gypsum contributes cooling and anti-inflammatory effects within the traditional framework. Together, the formula reduces excess fluid load on the heart and lungs while gently supporting cardiac output.
In Japan, Mokuboito is most commonly dispensed as a standardized granule (Tsumura or Kotaro brand extract granules) taken dissolved in hot water, which mirrors the traditional decoction method. Decoctions made from raw herbs are used by traditional practitioners. Extract powders and tablets are available for patient convenience but may vary in standardization.
Mokuboito originates from the classical Chinese medical text 'Jin Gui Yao Lue' (Essentials from the Golden Cabinet), compiled by Zhang Zhongjing around 220 AD. It was adopted into Japanese Kampo practice and remains one of the officially recognized Kampo formulas covered under Japan's national health insurance system, reflecting its enduring clinical relevance for cardiac and fluid conditions.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.